Samson Rock Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Samson Rock Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36,856	Closed	-$132K	–	46
2023 Q2	$132K	Buy	+36,856	New	+$118K	0.2%	16

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samson Rock Capital's ORMP Position: Q3 2023 in Review

Samson Rock Capital sold out of Oramed Pharmaceuticals (ORMP) in Q3 2023, closing a stake of 36,856 shares — an estimated $132K sold.

Samson Rock Capital first reported a position in ORMP in Q2 2023 and held it in 1 quarter. The position peaked at $132K in Q2 2023. 56 funds tracked by Wall St. Rank hold ORMP as of Q3 2023.

Samson Rock Capital reported no remaining Oramed Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Samson Rock Capital sold 36,856 Oramed Pharmaceuticals shares in Q3 2023, an estimated $132K.
Samson Rock Capital first reported a position in Oramed Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Samson Rock Capital's Oramed Pharmaceuticals position peaked at $132K in Q2 2023.
56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2023.

Based on Samson Rock Capital's 13F filing for Q3 2023, filed 14 Nov 2023.